These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 35551160)

  • 1. Case report: response to the ERK1/2 inhibitor ulixertinib in BRAF D594G cutaneous melanoma.
    Wolfe Z; Friedland JC; Ginn S; Blackham A; Demberger L; Horton M; McIntosh A; Sheikh H; Box J; Knoerzer D; Federowicz B; Stuhlmiller TJ; Shapiro M; Nair S
    Melanoma Res; 2022 Aug; 32(4):295-298. PubMed ID: 35551160
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting the MAPK Signaling Pathway in Cancer: Promising Preclinical Activity with the Novel Selective ERK1/2 Inhibitor BVD-523 (Ulixertinib).
    Germann UA; Furey BF; Markland W; Hoover RR; Aronov AM; Roix JJ; Hale M; Boucher DM; Sorrell DA; Martinez-Botella G; Fitzgibbon M; Shapiro P; Wick MJ; Samadani R; Meshaw K; Groover A; DeCrescenzo G; Namchuk M; Emery CM; Saha S; Welsch DJ
    Mol Cancer Ther; 2017 Nov; 16(11):2351-2363. PubMed ID: 28939558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Development of BRAF plus MEK Inhibitor Combinations.
    Subbiah V; Baik C; Kirkwood JM
    Trends Cancer; 2020 Sep; 6(9):797-810. PubMed ID: 32540454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Melanomas with concurrent BRAF non-p.V600 and NF1 loss-of-function mutations are targetable by BRAF/MEK inhibitor combination therapy.
    Rajkumar S; Berry D; Heney KA; Strong C; Ramsay L; Lajoie M; Alkallas R; Nguyen TT; Thomson C; Ahanfeshar-Adams M; Dankner M; Petrella T; Rose AAN; Siegel PM; Watson IR
    Cell Rep; 2022 Apr; 39(1):110634. PubMed ID: 35385748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells.
    Cesi G; Walbrecq G; Zimmer A; Kreis S; Haan C
    Mol Cancer; 2017 Jun; 16(1):102. PubMed ID: 28595656
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Sanchez IM; Purwin TJ; Chervoneva I; Erkes DA; Nguyen MQ; Davies MA; Nathanson KL; Kemper K; Peeper DS; Aplin AE
    Mol Cancer Ther; 2019 Sep; 18(9):1637-1648. PubMed ID: 31270153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pan-RAF and MEK vertical inhibition enhances therapeutic response in non-V600 BRAF mutant cells.
    Molnár E; Rittler D; Baranyi M; Grusch M; Berger W; Döme B; Tóvári J; Aigner C; Tímár J; Garay T; Hegedűs B
    BMC Cancer; 2018 May; 18(1):542. PubMed ID: 29739364
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular pathways: adaptive kinome reprogramming in response to targeted inhibition of the BRAF-MEK-ERK pathway in cancer.
    Johnson GL; Stuhlmiller TJ; Angus SP; Zawistowski JS; Graves LM
    Clin Cancer Res; 2014 May; 20(10):2516-22. PubMed ID: 24664307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor activity of extracellular signal-regulated kinases 1/2 inhibitor BVD-523 (ulixertinib) on thyroid cancer cells.
    Chen Y; Xiao X; Hu G; Liu R; Xue J
    J Cancer Res Ther; 2024 Apr; 20(2):570-577. PubMed ID: 38687926
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mitogen-activated protein kinase dependency in BRAF/RAS wild-type melanoma: A rationale for combination inhibitors.
    Ming Z; Lim SY; Kefford RF; Rizos H
    Pigment Cell Melanoma Res; 2020 Mar; 33(2):345-357. PubMed ID: 31518489
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protein Kinase CK2α Maintains Extracellular Signal-regulated Kinase (ERK) Activity in a CK2α Kinase-independent Manner to Promote Resistance to Inhibitors of RAF and MEK but Not ERK in BRAF Mutant Melanoma.
    Zhou B; Ritt DA; Morrison DK; Der CJ; Cox AD
    J Biol Chem; 2016 Aug; 291(34):17804-15. PubMed ID: 27226552
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulation of Brahma expression by the mitogen-activated protein kinase/extracellular signal regulated kinase pathway is associated with changes in melanoma proliferation.
    Mehrotra A; Saladi SV; Trivedi AR; Aras S; Qi H; Jayanthy A; Setaluri V; de la Serna IL
    Arch Biochem Biophys; 2014 Dec; 563():125-35. PubMed ID: 25026375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The BRAF(V600E) inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells.
    Jenkins MH; Croteau W; Mullins DW; Brinckerhoff CE
    Matrix Biol; 2015 Oct; 48():66-77. PubMed ID: 25989506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of Dabrafenib and Trametinib in a Patient with Squamous-Cell Carcinoma, with Mutation p.D594G in
    Grenda A; Krawczyk P; Targowska-Duda KM; Kieszko R; Paśnik I; Milanowski J
    Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674722
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway.
    Atefi M; von Euw E; Attar N; Ng C; Chu C; Guo D; Nazarian R; Chmielowski B; Glaspy JA; Comin-Anduix B; Mischel PS; Lo RS; Ribas A
    PLoS One; 2011; 6(12):e28973. PubMed ID: 22194965
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loss of Spry1 reduces growth of BRAF
    Montico B; Colizzi F; Giurato G; Rizzo A; Salvati A; Baboci L; Benedetti D; Pivetta E; Covre A; Bo MD; Weisz A; Steffan A; Maio M; Sigalotti L; Fratta E
    Cell Death Dis; 2020 May; 11(5):392. PubMed ID: 32444628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of cell type-specific correlations between ERK activity and cell viability upon treatment with ERK1/2 inhibitors.
    Lebedev TD; Khabusheva ER; Mareeva SR; Ivanenko KA; Morozov AV; Spirin PV; Rubtsov PM; Snezhkina AV; Kudryavtseva AV; Sorokin MI; Buzdin AA; Prassolov VS
    J Biol Chem; 2022 Aug; 298(8):102226. PubMed ID: 35787369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted Therapy for Melanomas Without BRAF V600 Mutations.
    Menzer C; Hassel JC
    Curr Treat Options Oncol; 2022 Jun; 23(6):831-842. PubMed ID: 35380338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma proteome alterations by MAPK inhibitors in BRAF
    Babačić H; Eriksson H; Pernemalm M
    Neoplasia; 2021 Aug; 23(8):783-791. PubMed ID: 34246984
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib.
    Acquaviva J; Smith DL; Jimenez JP; Zhang C; Sequeira M; He S; Sang J; Bates RC; Proia DA
    Mol Cancer Ther; 2014 Feb; 13(2):353-63. PubMed ID: 24398428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.